~~<i id='224D91C60E'><strike id='224D91C60E'><tt id='224D91C60E'><pre id='224D91C60E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：fashion 2025-10-01 00:52:30 - browse：1

Photo illustration of a single pill on a large white field – opinion coverage from STAT — Adobe

This time last year, members of Congress were working around the clock to draft and pass the Inflation Reduction Act.

One of their goals was to address government spending on health care. But they specifically didn’t want to discourage research into rare disease treatments, so they exempted some of these so-called orphan drugs from the law.

Unfortunately, the exemptions aren’t working as intended. Unless Congress acts, the IRA threatens to unravel one of America’s greatest medical and public policy success stories: the explosion of new treatments for patients living with rare diseases.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： A clever new way to fix Medicaid and graduate medical education

explore

entertainment

leisure time

focus

knowledge

Walmartseemspoisedtoincreaseitshealthcarefootprintbybuyingvalue-basedseniorcarecompanyChenMed.JoeRae

WSS

The new shift in health care is toward less care

Walmart eyes Medicare Advantage provider ChenMed

Sanofi CEO defends move to abandon profit guidance, boost research

How to make the FDA’s new prescription one

Senate panel clears PBM, hopsital reforms

UCSF medical school apologizes for unethical prisoner experiments

leisure time

leisure time

explore

How to save PrEP access — and even expand it

FDA approves Recor Medical high blood pressure device

United colonoscopy coverage change 'may cost lives,' doctors say

New weight loss drugs vying to be the next Wegovy or Mounjaro

Medical records are filled with copy

Acelyrin, a rare IPO success, stumbles in its first big test

Heart attack and stroke risk calculators need revising

Telehealth for opioid use disorder is lifesaving

In age of alternative facts, a scholarly course on calling out crap

Biotech incubator Curie.Bio graduates its first startup

entertainment

Abortion clinic in Cancun will cater to Americans

What to make of Biden’s latest efforts on cancer research

How to make the FDA’s new prescription one

Acelyrin, a rare IPO success, stumbles in its first big test

New weight loss drugs vying to be the next Wegovy or Mounjaro

White House touts steps to stem shortages of cancer treatments

leisure time

focus

focus

knowledge